The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effects of Exposure to Selective Serotonin Reuptake Inhibitors During Pregnancy on Serotonergic Symptoms in Newborns and Cord Blood Monoamine and Prolactin Concentrations
Open accessAbstract
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) have gained wide acceptance in the treatment of mental disorders in pregnant women, but there seems to be an increased risk for neonatal adaptation problems after exposure to SSRIs in late pregnancy. We aimed to investigate the perinatal sequelae of infants exposed to SSRIs during their fetal life and the relationship of these symptoms to the cord blood monoamine and prolactin concentrations. METHODS: We conducted a prospective, controlled, follow-up study with 20 mothers taking 20 to 40 mg/d of either citalopram or fluoxetine for depression (n = 10) or panic disorder (n = 10) and their infants and 20 matched controls not receiving psychotropic medication for confounding obstetric characteristics. Maternal cord blood and infant citalopram, fluoxetine, and norfluoxetine, cord blood monoamine and metabolite, and prolactin concentrations were measured. The newborns underwent standard clinical examination and specific assessment of serotonergic symptoms during the first 4 days of life and at the ages of 2 weeks and 2 months. RESULTS: There was a statistically significant (P =.008, V = 15, n = 20 for both groups), 4-fold difference in the serotonergic symptom score during the first 4 days of life between the SSRI group and the control group. The SSRI-exposed infants had significantly lower cord blood 5-hydroxyindoleacetic acid (5-HIAA) concentrations (P =.02, t31 = 2.57) compared with the control group. A significant inverse correlation (rs = -0.66, P =.007, n = 15) was seen between the serotonergic symptom score and the umbilical vein 5-HIAA concentrations in the SSRI-exposed but not the control infants. CONCLUSIONS: Infants exposed to SSRIs during late pregnancy are at increased risk for serotonergic central nervous system adverse effects, and the severity of these symptoms is significantly related to cord blood 5-HIAA levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.6.705 · Cited by 1,342
Birth Outcomes in Pregnant Women Taking Fluoxetine
Chambers, C. D., Johnson, K. A., Dick, L. M., Felix, R. J., & Jones, K. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351402 · Cited by 735
Prechtl, H. F. R. (1990) · Early Human Development · doi:10.1016/0378-3782(90)90011-7 · Cited by 612
Neurodevelopment of Children Exposed in Utero to Antidepressant Drugs
Nulman, I., Rovet, J., Stewart, D. E., Wolpin, J., Gardner, H. A., Theis, J. G. W., Kulin, N., & Koren, G. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701233360404 · Cited by 573
Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)
Hyttel, J. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199403001-00004 · Cited by 492 · cited 3×
“SSRI dose during pregnancy, mg/d† Citalopram 20 (20-40) NA NA Fluoxetine 20 (20-40) NA NA Concomitant occasional use, No.”
BackgroundKulin, N. A., Pastuszak, A., Sage, S. R., Schick-Boschetto, B., Spivey, G., Feldkamp, M., Ormond, K., Matsui, D., Stein-Schechman, A. K., Cook, L., et al. (1998) · JAMA · doi:10.1001/jama.279.8.609 · Cited by 424
Pregnancy Outcome Following First-Trimester Exposure to Fluoxetine (Prozac)
Pastuszak, A. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500170076037 · Cited by 368
Delivery outcome after the use of antidepressants in early pregnancy
Ericson, A., Källén, B., & Wiholm, B.-E. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050664 · Cited by 284
Depression during pregnancy and the puerperium.
Llewellyn, A., Stowe, Z. N., & Nemeroff, C. B. (1997) · PubMed · Cited by 226
Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.
(2000) · PubMed Central · Cited by 207
Onset of obsessive-compulsive disorder in pregnancy
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.7.947 · Cited by 192
Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors
Nordeng, H., Lindemann, R., Perminov, K. V., & Reikvam1, Å. (2001) · Acta Paediatrica · doi:10.1080/080352501300067596 · Cited by 181
The serotonin syndrome scale: first results on validity
Hegerl, U., Bottlender, R., Gallinat, J., Kuss, H.-J., Ackenheil, M., & Möller, H.-J. (1998) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060050024 · Cited by 180
Use of Psychoactive Medication During Pregnancy and Possible Effects on the Fetus and Newborn
(2000) · PEDIATRICS · doi:10.1542/peds.105.4.880 · Cited by 140
Birth outcomes following prenatal exposure to fluoxetine
Cohen, L. S., Heller, V. L., Bailey, J. W., Grush, L. R., Ablon, J. S., & Bouffard, S. M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00877-5 · Cited by 137
Fluoxetine Hydrochloride (Prozac) Toxicity in a Neonate
SPENCER, M. J. (1993) · PEDIATRICS · doi:10.1542/peds.92.5.721 · Cited by 121
Potter, W. Z. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790350045009 · Cited by 118
Scheinin, M., Karhuvaara, S., Ojala-Karlsson, P., Kallio, A., & Koulu, M. (1991) · Life Sciences · doi:10.1016/0024-3205(91)90581-u · Cited by 97
Serum Fluoxetine and Norfluoxetine Concentrations and Antidepressant Response
Kelly, M. W., Perry, P. J., Holstad, S. G., & Garvey, M. J. (1989) · Therapeutic Drug Monitoring · doi:10.1097/00007691-198903000-00008 · Cited by 81
Sarrias, M. J., Cabré, P., Martı́nez, E., & Artigas, F. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02319.x · Cited by 81
Cowen, P. J., & Sargent, P. A. (1997) · Journal of Psychopharmacology · doi:10.1177/026988119701100410 · Cited by 78
Paroxetine withdrawal syndrome in a neonate
Dahl, M. L., Olhager, E., & Ahlner, J. (1997) · The British Journal of Psychiatry · doi:10.1192/bjp.171.4.391c · Cited by 67
Suspected congenital sertraline dependence
Kent, L., & Laidlaw, J. (1995) · The British Journal of Psychiatry · doi:10.1192/bjp.167.3.412b · Cited by 64
Biochemical effects of zimelidine in man
Bertilsson, L., Tuck, J. R., & Siwers, B. (1980) · European Journal of Clinical Pharmacology · doi:10.1007/bf00874660 · Cited by 61
Potential Fluoxetine Chloride (Prozac) Toxicity in a Newborn
Mhanna, M. J., Bennet, J., & Izatt, S. D. (1997) · PEDIATRICS · doi:10.1542/peds.100.1.158 · Cited by 60
Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome?
Isbister, G. K., Dawson, A. H., Whyte, I. M., Prior, F. H., CLANCY, C., & SMITH, A. J. (2001) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/fn.85.2.f145g · Cited by 59
The impact of pregnancy and puerperium on panic disorder: A review
Hertzberg, T., & Wahlbeck, K. (1999) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.3109/01674829909075578 · Cited by 53
Lack of Adverse Interactions Between Concomitantly Administered Selegiline and Citalopram
Laine, K., Anttila, M. I., Heinonen, E. H., Helminen, A., Huupponen, R., Mäki-Ikola, O., Reinikainen, K. J., & Scheinin, M. (1997) · Clinical Neuropharmacology · doi:10.1097/00002826-199710000-00006 · Cited by 51
Self-citation
Cited by
Boyer, E. W., & Shannon, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041867 · Cited by 1,821
Cohen, L. S. (2006) · JAMA · doi:10.1001/jama.295.5.499 · Cited by 1,031
Hudak, M. L., Tan, R. C., THE COMMITTEE ON DRUGS, THE COMMITTEE ON FETUS AND NEWBORN, Frattarelli, D. A. C., Galinkin, J. L., Green, T. P., Neville, K. A., Paul, I. M., Van Den Anker, J. N., et al. (2012) · Pediatrics · doi:10.1542/peds.2011-3212 · Cited by 877
Oberlander, T. F., Warburton, W., Misri, S., Aghajanian, J., & Hertzman, C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.898 · Cited by 551
Moses-Kolko, E. L., Bogen, D., Perel, J., Bregar, A., Uhl, K., Levin, B., & Wisner, K. L. (2005) · JAMA · doi:10.1001/jama.293.19.2372 · Cited by 533
Metadata
- Authors
- Laine, K., Heikkinen, T., Ekblad, U., & Kero, P.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2003-07-01
- Volume
- 60
- Issue
- 7
- Pages
- 720
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2045082465
- Cited by
- 331
- References
- 28
- FWCI
- 25.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.